Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round

Jeito Capital turns into key investor in Alentis Therapeutics as a part of $67 million Sequence B financing spherical

• Jeito Capital selects Alentis Therapeutics as its fifth funding since launching the fund
• Alentis is targeted on the event of breakthrough remedies for fibrotic illnesses and related cancers

Paris, France,
15
June
2021 – Jeito Capital (“Jeito”), a quickly rising unbiased Non-public Fairness agency devoted to biotech and biopharma, in the present day pronounces that it has turn out to be a key investor as a part of a $67 million Sequence B financing spherical in Alentis Therapeutics (Alentis). The Swiss biotech firm, a spin-off of French Inserm with R&D in Strasbourg, France, is creating breakthrough therapies for sufferers affected by fibrotic illnesses and related cancers.

Proceeds from the financing spherical will probably be used for proof-of-concept medical trials of Alentis’ first-in-class property, uniquely concentrating on fibrosis pathways for the remedy of life-threatening superior liver and kidney fibrosis in addition to related cancers. Alentis expects to provoke its first medical trial by the tip of 2021.

Jeito’s funding goals to allow Alentis to speed up the medical pathway for numerous indications, with the potential to supply life-changing remedies to severely sick sufferers who haven’t any different choices. The funding may even give the Firm the chance to broaden its pipeline and discover additional indications, together with fibrotic related cancers.

The financing spherical brings in Jeito Capital and Morningside Enterprise Investments alongside present traders BioMed Companions, BB Pureos Bioventures, Bpifrance, Excessive-Tech Gründerfonds and Schroders Capital. Following the fundraise, Rafaèle Tordjman, Founder and CEO of Jeito Capital, will be a part of Alentis’ Board of Administrators.

That is Jeito’s fifth funding since launching its fund in 2020. With greater than €250 million underneath administration, Jeito Capital is constructing a robust and diversified portfolio in biotech and biopharma firms based mostly in Europe with world attain targeted on the remedy of life-threatening illnesses. Earlier investments embrace French firms SparingVision and InnoSkel, respectively within the fields of ophthalmology and uncommon skeletal problems, Dutch biotech Neogene Therapeutics in stable tumors, and not too long ago Pulmocide in respiratory illnesses, based mostly within the UK.

Alentis is led by a extremely skilled administration group from the biotech and pharma industries. The Firm’s science relies on greater than 10 years of analysis by founder Thomas Baumert, a world class hepatology knowledgeable who presently serves as the pinnacle of Inserm’s Institute of Viral and Liver Ailments. Prof. Baumert’s analysis in Claudin-1 is exclusive and, till now, has not been explored as a possible remedy goal for fibrotic illnesses.

Rafaèle Tordjman, founder and CEO of Jeito, mentioned: “Our funding in Alentis at this pivotal time of growth
will probably be essential for its success and we’re wanting ahead to working intently alongside their
very skilled group.
Our experience lies in serving to administration groups from the science proper by to commercialization of the product and right here we’ll intention to speed up Alentis’ efforts in the direction of the initiation of the company’s first medical trials.
This represents our fifth
funding in our numerous portfolio and strengthens our dedication to investing in European biotechs working in the direction of the event of life–saving property focused at illnesses with unmet want based mostly on excellent science.”

Dr. Roberto Iacone, Chief Govt Officer at Alentis Therapeutics, mentioned: “We’re delighted to have closed this financing spherical with new traders Jeito Capital and Morningside Enterprise Investments, two effectively respected and extremely educated establishments throughout the healthcare area who will convey invaluable expertise to the Board as we progress in the direction of the initiation of our first medical trials. Constructing on
20 years of labor and optimistic preclinical knowledge collected on ALE.F02, we are assured within the success of the upcoming trials as we work with each new and present traders in the direction of commercialization, providing
a a lot wanted secure and efficient remedy to sufferers affected by fibrotic illnesses and hepatobiliary cancers.”

ENDS

About Jeito Capital
Jeito Capital is a world main funding firm with a affected person profit pushed method that funds and accelerates ground-breaking medical innovation. Jeito empowers and helps entrepreneurs by its knowledgeable, built-in, multi-talented group and thru the funding of serious capital to make sure the expansion of firms, constructing market leaders of their respective therapeutic areas with accelerated sufferers’ entry in Europe & america. Jeito Capital relies in Paris with a presence in Europe and america. For extra info, please go to www.jeito.life, or observe on Twitter @Jeito_life or LinkedIn.

About Alentis Therapeutics
Alentis Therapeutics is a Swiss-based biotech that focuses on creating breakthrough remedies for fibrotic illnesses. The corporate was based in 2019 based mostly on ground-breaking analysis within the laboratory of Prof. Thomas Baumert MD on the College of Strasbourg and the French Nationwide Institute of Well being (Inserm).

The corporate’s lead candidates are monoclonal antibodies which are extremely selective for Claudin-1, a novel, beforehand unexploited goal with a novel mechanism of motion that performs a key position within the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers. It additionally has early discovery packages exploring the potential of Claudin-1 inhibition within the remedy of fibrosis of different tissues together with the kidney and lung. These characterize very giant and increasing markets with excessive unmet want. Moreover, the corporate makes use of a patient-derived drug and goal discovery platform to develop medicines for superior fibrosis.

In contrast to present therapies in fibrosis, which largely tackle the illness not directly, Alentis’ pioneering method has the potential to straight modify and reverse the course of illness development.

Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France.

For extra info, go to https://alentis.ch/

For extra info please contact: